Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 31, 2000

Study Completion Date

October 31, 2006

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

carmustine

DRUG

efaproxiral

Trial Locations (9)

30322

Winship Cancer Institute of Emory University, Atlanta

35294

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

48202

Josephine Ford Cancer Center at Henry Ford Hospital, Detroit

33612-9497

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

02114

Massachusetts General Hospital Cancer Center, Boston

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

78229-3900

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

New Approaches to Brain Tumor Therapy Consortium

OTHER

NCT00005855 - Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter